The latest quarterly filing dated June 15, 2026, reveals ongoing net losses totaling $1.87 million for the nine months ended April 30, 2026, with revenues at $1.66 million, signaling persistent cash burn and liquidity constraints that place the company’s operational continuity under pressure. Despite these headwinds, PURE Bioscience’s core business remains anchored in its patented Silver Dihydrogen Citrate (SDC) platform, offering broad-spectrum antimicrobial efficacy with favorable safety and environmental profiles. The company operates in specialty antimicrobials primarily servicing the food processing and healthcare sectors through EPA-registered disinfectants and FDA-approved processing aids, leveraging direct sales combined with an expanding distributor network. Regulatory approvals and successful in-plant validation trials are pivotal growth levers but entail long sales cycles and capital demands, forming a dual narrative of technological promise versus financial sustainability risk.